Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Germinal Center B-cell Type
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

Drugs mentioned

• ViPOR

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING